Innate Pharma : Erratum (English Version)

INNATE PHARMA

ERRATUM

1. Notice of meeting brochure for the extraordinary and ordinary General Meeting of May 28, 2021

Section 8 "Text of resolutions" - Modification of the by-laws - Resolution n° 33 - Amendment of the Articles of Association - p.50.

In accordance with the Notice of Meeting of the General Meeting of 28 May 2021, "The purpose of resolution no. 33 is to amend Article 19.I. of the Company's by-lawsin order to modify the quorum and majority required for the Executive Board to take decisions and to authorize written consultations" should be read as "The purpose of resolution no. 33 is to amend

Article 19.I. of the Company's by-laws in order to authorize voting by videoconference for decisions concerning the verification and supervisions of half-yearly or quarterly financial statements and to authorize written consultations".

2. Report of the Executive Board at the Annual Shareholders' Meeting of 28 May 2021

Annex 2: Governance Report (Section 2 - Say on Pay) - Section 2.1.1.4. Annual variable compensation - p.28.

The table below:

Maximum compensation

Maximum percentage of the fixed remuneration if:

Maximum amount of variable compensation (in Euros) if:

Executive Board members	100%	Maximum over-	100% of objective are	Maximum over-
	objectives are	performance (150%)	reached	performance + than
	reached			100% (max 150%)
Chairman of the Executive Board	60%	90%	€282,000	€535,800
Executive Board member	40%	60%	€96,000	€153,600
"Product portfolio strategy & Business
development"

Should be read as:

Maximum compensation

Maximum percentage of the fixed remuneration if:

Maximum amount of variable compensation (in Euros) if:

Executive Board members	100%	Maximum over-	100% of objective are	Maximum over-
	objectives are	performance (150%)	reached	performance + than
	reached			100% (max 150%)
Chairman of the Executive Board	60%	90%	€282,000	€423,000
Executive Board member	40%	60%	€96,000	€144,000
"Product portfolio strategy & Business
development"